Are China Hospital Purchases Slowing? Ask Mindray
This article was originally published in The Gray Sheet
China’s largest medical device maker surprised everyone by posting overall second-quarter net revenue growth of 9 percent, to $334.5 million, amid challenging market conditions. It expects a further recovery in the second half, but conditions at home remain difficult.
You may also be interested in...
According to plaintiffs in California federal court, P&G’s claims on Herbal Essences and Pantene shampoo and conditioner products about high proportions of natural-origin or naturally derived ingredients are false and/or misleading, and ISO 16128 certification does not cure the deception.
Perelel doubles its support and makes $10m pledge to women’s health research groups; Odyssey Wellness starts boosting brand visibility for energy drinks with lion’s mane and cordyceps mushrooms.
Following request by Universities Allied for Essential Medicines, FDA creates a public dashboard of pre-notices of noncompliance on registering trials and submitting results to ClinicalTrials.gov. The agency denies request to impose civil penalties on those who fail to comply, citing its discretion.